|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||164.67 - 167.87|
|52 Week Range||136.50 - 194.92|
|Beta (3Y Monthly)||1.69|
|PE Ratio (TTM)||65.96|
|Earnings Date||Jan 29, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||196.32|
Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease.
NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Jazz Pharmaceuticals generated revenues of $469.4 million in the third quarter, which reflects ~14% YoY (year-over-year) growth. Jazz Pharmaceuticals’ net revenues over the first nine months of 2018 were $1.4 billion—compared to $1.2 billion in the same period in 2017, which reflects ~20% YoY growth.
CRISPR Therapeutics (CRSP) reported a net income of -$50.7 million in the third quarter—compared to a net income of -$24.7 million in the third quarter of 2017. CRISPR Therapeutics’ net income over the first nine months of 2018 was -$117.4 million—compared to -$68.5 million in the same period in 2017.
Perrigo (PRGO) reports mixed third-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018 for the second straight quarter.
Biotech stocks may be nearing a significant break out using the SPDR Biotech ETF ( XBI) as a proxy. Esperion has broken out already after rising above technical resistance at $50.75. Now the chart suggests the stock may rise back to $69 to fill that gap, and should that happen it would result in a 17% gain from the current stock price of $58.86.
Editas Medicine could be the next to test the widely watched gene editing technology CRISPR/Cas9 after filing a clinical trial application late last month, the company revealed Wednesday.
Geron (GERN) beats earnings estimates in the third quarter but misses on revenues. Operating expenses decrease year over year.
Seismic changes in global economies and the stock market are forcing investors to look at new ways to find companies that can add value long term, over multiple years, by adapting to these economic and market upheavals. To this end, The Boston Consulting Group (BCG) and Fortune magazine have created the Fortune Future 50, "the global companies with the best prospects for future growth." As Martin Reeves, a senior partner at BCG, writes in Fortune: "Our index is forward-looking, in the sense that it aims to measure vitality--a company's capacity to reinvent its business and sustain revenue growth. Among the stocks on this list are these 9: Vertex Pharmaceuticals Inc. ( VRTX), NetEase Inc. ( NTES), Salesforce.com Inc. ( CRM), Weibo Corp. ( WB), Geely Automobile Holdings Ltd. (GELYF), Amazon.com Inc. ( AMZN), Microchip Technology Inc. ( MCHP), Nvidia Corp. ( NVDA), and JD.com Inc. ( JD).
The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals
- A new treatment option for patients with two copies of the F508del mutation, the most common mutation in cystic fibrosis -
Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Vertex Pharmaceuticals (VRTX) released its third quarter of fiscal 2018 results on October 24. Its cystic fibrosis revenues increased an impressive 42% to $783 million, from $550 million in Q3 2017.
NEW YORK, NY / ACCESSWIRE / October 25, 2018 / U.S. stocks plunged on Wednesday as a sharp selloff in technology shares was triggered by losses from the FANG stocks (Facebook, Amazon, Netflix and Google ...
On a per-share basis, the Boston-based company said it had net income of 50 cents. Earnings, adjusted for stock option expense and non-recurring costs, were $1.09 per share. The results beat Wall Street ...